Journal ArticleDOI
Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies.
M. W. M. D. Lutgens,Martijn G.H. van Oijen,Geert J. M. G. van der Heijden,Frank P. Vleggaar,Peter D. Siersema,Bas Oldenburg +5 more
Reads0
Chats0
TLDR
The risk of CRC is increased in patients with IBD but not as high as previously reported and not in all patients, and this decline could be the result of aged cohorts.Abstract:
Background Recently reported risks of colorectal cancer (CRC) in inflammatory bowel disease (IBD) have been lower than those reported before 2000. The aim of this meta-analysis was to update the CRC risk of ulcerative and Crohn's colitis, investigate time trends, and identify high-risk modifiers. Methods The MEDLINE search engine was used to identify all published cohort studies on CRC risk in IBD. Publications were critically appraised for study population, Crohn's disease localization, censoring for colectomy, and patient inclusion methods. The following data were extracted: total and stratified person-years at risk, number of observed CRC, number of expected CRC in background population, time period of inclusion, and geographical location. Pooled standardized incidence ratios and cumulative risks for 10-year disease intervals were calculated. Results were corrected for colectomy and isolated small bowel Crohn's disease. Results The pooled standardized incidence ratio of CRC in all patients with IBD in population-based studies was 1.7 (95% confidence interval [CI], 1.2-2.2 ). High-risk groups were patients with extensive colitis and an IBD diagnosis before age 30 with standardized incidence ratios of 6.4 (95% confidence interval, 2.4-17.5) and 7.2 (95% confidence interval, 2.9-17.8), respectively. Cumulative risks of CRC were 1%, 2%, and 5% after 10, 20, and >20 years of disease duration, respectively. Conclusions The risk of CRC is increased in patients with IBD but not as high as previously reported and not in all patients. This decline could be the result of aged cohorts. The risk of CRC is significantly higher in patients with longer disease duration, extensive disease, and IBD diagnosis at young age.read more
Citations
More filters
Journal ArticleDOI
Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors
TL;DR: According to GLOBOCAN 2018 data, colorectal cancer (CRC) is the third most deadly and fourth most commonly diagnosed cancer in the world.
Journal ArticleDOI
ACG Clinical Guideline: Ulcerative Colitis in Adults
TL;DR: These guidelines indicate the preferred approach to the management of adults with UC and represent the official practice recommendations of the American College of Gastroenterology.
Journal ArticleDOI
Cancers Complicating Inflammatory Bowel Disease
TL;DR: The wide range of cancers associated with inflammatory bowel disease and the drugs used to manage them are reviewed and surveillance recommendations are presented.
Journal ArticleDOI
Global colorectal cancer burden in 2020 and projections to 2040
Yue Xi,Pengfei Xu +1 more
TL;DR: In this article, the authors present the global epidemiology of colorectal cancer in 2020 and projections for 2040, review the major CRC subtypes to better understand CRC molecular basis, and summarize current risk factors, prevention, and screening strategies for CRC.
Journal ArticleDOI
European evidence-based consensus: Inflammatory bowel disease and malignancies
Vito Annese,Laurent Beaugerie,Laurence J. Egan,Livia Biancone,Claus Bolling,Christian Brandts,Daan Dierickx,Reinhard Dummer,Gionata Fiorino,Jean Marc Gornet,Peter D.R. Higgins,Konstantinos Katsanos,Loes H C Nissen,Gianluca Pellino,Gerhard Rogler,Franco Scaldaferri,Edyta Szymanska,Rami Eliakim +17 more
TL;DR: It is the Committee’s hope that these statements will facilitate and accelerate future efforts to elaborate formal guidelines, providing useful information on areas for which evidence is lacking and where controlled studies are needed.
References
More filters
Journal Article
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
TL;DR: The QUOROM Statement (QUality Of Reporting Of Meta-analyses) as mentioned in this paper was developed to address the suboptimal reporting of systematic reviews and meta-analysis of randomized controlled trials.
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
TL;DR: A structured summary is provided including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings.
Journal ArticleDOI
Quantifying heterogeneity in a meta‐analysis
TL;DR: It is concluded that H and I2, which can usually be calculated for published meta-analyses, are particularly useful summaries of the impact of heterogeneity, and one or both should be presented in publishedMeta-an analyses in preference to the test for heterogeneity.
Journal ArticleDOI
The risk of colorectal cancer in ulcerative colitis: a meta-analysis
TL;DR: Using new meta-analysis techniques, the risk of CRC in UC by decade of disease and defined the risk in pancolitics and children was determined and how risk varies with geography was estimated.
Journal ArticleDOI
Ulcerative colitis and colorectal cancer. A population-based study.
TL;DR: Close surveillance and perhaps even prophylactic proctocolectomy should be recommended for patients given a diagnosis of pancolitis, especially those who are less than 15 years of age at diagnosis.